<DOC>
	<DOC>NCT02077192</DOC>
	<brief_summary>The purpose of this study is to determine whether fostamatinib is safe and effective in treating patients with persistent/chronic Immune Thrombocytopenic Purpura (ITP) over a 2 year period.</brief_summary>
	<brief_title>Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)</brief_title>
	<detailed_description />
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<criteria>Completed or discontinued early from Study C935788047 or Study C935788 048 Able and willing to give written informed consent Discontinued participation in Study C935788047 or Study C935788048 for any reason other than lack of response Poorly controlled hypertension during Study C935788047 or Study C935788048 Significant infection, an acute infection such as influenza, or known inflammatory process</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>